全文获取类型
收费全文 | 21343篇 |
免费 | 1744篇 |
国内免费 | 76篇 |
专业分类
耳鼻咽喉 | 314篇 |
儿科学 | 595篇 |
妇产科学 | 463篇 |
基础医学 | 3004篇 |
口腔科学 | 445篇 |
临床医学 | 1990篇 |
内科学 | 5018篇 |
皮肤病学 | 239篇 |
神经病学 | 2008篇 |
特种医学 | 647篇 |
外科学 | 3399篇 |
综合类 | 302篇 |
一般理论 | 16篇 |
预防医学 | 1621篇 |
眼科学 | 582篇 |
药学 | 1156篇 |
中国医学 | 38篇 |
肿瘤学 | 1326篇 |
出版年
2023年 | 182篇 |
2022年 | 386篇 |
2021年 | 777篇 |
2020年 | 405篇 |
2019年 | 612篇 |
2018年 | 739篇 |
2017年 | 483篇 |
2016年 | 495篇 |
2015年 | 607篇 |
2014年 | 787篇 |
2013年 | 1037篇 |
2012年 | 1503篇 |
2011年 | 1525篇 |
2010年 | 830篇 |
2009年 | 708篇 |
2008年 | 1251篇 |
2007年 | 1235篇 |
2006年 | 1222篇 |
2005年 | 1154篇 |
2004年 | 1064篇 |
2003年 | 933篇 |
2002年 | 922篇 |
2001年 | 151篇 |
2000年 | 137篇 |
1999年 | 165篇 |
1998年 | 180篇 |
1997年 | 165篇 |
1996年 | 137篇 |
1995年 | 126篇 |
1994年 | 117篇 |
1993年 | 113篇 |
1992年 | 108篇 |
1991年 | 102篇 |
1990年 | 111篇 |
1989年 | 90篇 |
1988年 | 106篇 |
1987年 | 113篇 |
1986年 | 76篇 |
1985年 | 106篇 |
1984年 | 106篇 |
1983年 | 102篇 |
1982年 | 135篇 |
1981年 | 125篇 |
1980年 | 164篇 |
1979年 | 77篇 |
1978年 | 87篇 |
1977年 | 79篇 |
1976年 | 84篇 |
1975年 | 63篇 |
1974年 | 71篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
991.
Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy
Samuel Stuart PhD Rosie Morris PhD Andrew Giritharan MD Joseph Quinn MD John G. Nutt MD Martina Mancini PhD 《Movement disorders》2020,35(11):2019-2027
Degradation of striatal dopamine in Parkinson's disease (PD) may initially be supplemented by increased cognitive control mediated by cholinergic mechanisms. Shift to cognitive control of walking can be quantified by prefrontal cortex activation. Levodopa improves certain aspects of gait and worsens others, and cholinergic augmentation influence on gait and prefrontal cortex activity remains unclear. This study examined dopaminergic and cholinergic influence on gait and prefrontal cortex activity while walking in PD. A single-site, randomized, double-blind crossover trial examined effects of levodopa and donepezil in PD. Twenty PD participants were randomized, and 19 completed the trial. Participants were randomized to either levodopa + donepezil (5 mg) or levodopa + placebo treatments, with 2 weeks with treatment and a 2-week washout. The primary outcome was change in prefrontal cortex activity while walking, and secondary outcomes were change in gait and dual-task performance and attention. Levodopa decreased prefrontal cortex activity compared with off medication (effect size, −0.51), whereas the addition of donepezil reversed this decrease. Gait speed and stride length under single- and dual-task conditions improved with combined donepezil and levodopa compared with off medication (effect size, 1 for gait speed and 0.75 for stride length). Dual-task reaction time was quicker with levodopa compared with off medication (effect size, −0.87), and accuracy improved with combined donepezil and levodopa (effect size, 0.47). Cholinergic therapy, specifically donepezil 5 mg/day for 2 weeks, can alter prefrontal cortex activity when walking and improve secondary cognitive task accuracy and gait in PD. Further studies will investigate whether higher prefrontal cortex activity while walking is associated with gait changes. © 2020 International Parkinson and Movement Disorder Society 相似文献
992.
Guadalupe Muñoz-Arenas Guadalupe Pulido Samuel Treviño Rubén Vázquez-Roque Gonzalo Flores Carolina Moran Anabella Handal-Silva Jorge Guevara Berenice Venegas Alfonso Díaz 《Synapse (New York, N.Y.)》2020,74(9):e22153
Metabolic syndrome (MS) is a health problem that is characterized by body fat accumulation, hypertension, dyslipidemia, and hyperglycemia; recently, it has been demonstrated that MS also damages memory processes. The first-line drug in the treatment of MS and type 2 diabetes mellitus is metformin, which is an antihyperglycemic agent. This drug has been shown to produce neuroprotection and to improve memory processes. However, the mechanism involved in this neuroprotection is unknown. A 90-day administration of metformin improved the cognitive processes of rats with MS as evaluated by the novel object recognition test, and this finding could be explained by an increase in the neuronal spine density and spine length. We also found that metformin increased the immunoreactivity of synaptophysin, sirtuin-1, AMP-activated protein kinase, and brain-derived neuronal factor, which are important plasticity markers. We conclude that metformin is an important therapeutic agent that increases neural plasticity and protects cognitive processes. The use of this drug is important in the minimization of the damage caused by MS. 相似文献
993.
994.
995.
Bergman David Modh Ankit Schultz Lonni Snyder James Mikkelsen Tom Shah Mira Ryu Samuel Siddiqui M. Salim Walbert Tobias 《Journal of neuro-oncology》2020,148(2):353-361
Journal of Neuro-Oncology - Outcomes for patients with recurrent high-grade glioma (HGG) progressing on bevacizumab (BEV) are dismal. Fractionated stereotactic radiosurgery (FSRS) has been shown to... 相似文献
996.
Joanne E. Mortimer Laura Kruper Jae Jung Louise Wong Jill Cooper Daphne Stewart Samuel Chung Kim Wai Yu Sanjeet Dadwal Yuan Yuan 《Cancer chemotherapy and pharmacology》2020,85(3):501-507
We update a patient series that reported a high incidence of infection with Gram-positive cocci in women treated with the combination of pertuzumab and trastuzumab and further characterize this clinical problem.
Treating physicians and advanced practice partners identified women who developed infections while on treatment with pertuzumab and trastuzumab alone or in combination with chemotherapy and enrolled them onto this registry trial. Between March, 2014 and May, 2017, 48 patients with HER2-positive breast cancers were reported to have 59 individual infections. The median age was 48 years. Twenty-four patients received neoadjuvant therapy, 17 were treated for metastatic disease, and 7 were treated in the adjuvant setting. Pertuzumab and trastuzumab were combined with carboplatin and docetaxel in 24 (49%) patients, docetaxel in 10 (21%), nab-paclitaxel in 12 (24%), and without other agents in 2 (4%). Granulocyte growth factors were administered in 24 (49%) patients and no patients were documented to be neutropenic. Folliculitis developed in 25 (52%) patients and was counted as a single infection. Abscesses developed at a number of sites in 24 (49%) patients, including a septic knee requiring total knee replacement. Paronychia occurred in 7 (15%) patients, and 5 (10%) developed cellulitis. When cultures were obtained, Gram-positive cocci were consistently identified. Hypogammaglobulinemia was documented in 14 (36%) of the 33 patients tested. Our data continue to support an increased risk of infections with Gram-positive cocci as a potentially serious adverse event in women treated with pertuzumab and trastuzumab. 相似文献
997.
Umut Disel Russell Madison Kumar Abhishek Jon H. Chung Sally E. Trabucco Asli O. Matos Garrett M. Frampton Lee A. Albacker Venkataprasanth Reddy Nuri Karadurmus Adam Benson Jennifer Webster Semra Paydas Ruben Cabanillas Chaitali Nangia M.A. Ozturk Sherri Z. Millis Sumanta K. Pal Breelyn Wilky Ethan S. Sokol Laurie M. Gay Salil Soman Shridar Ganesan Katherine Janeway Phil J. Stephens Viola W. Zhu Sai-Hong Ignatius Ou Christine M. Lovly Mrinal Gounder Alexa B. Schrock Jeffrey S. Ross Vincent A. Miller Samuel J. Klempner Siraj M. Ali 《The oncologist》2020,25(1):e39-e47
998.
Johanna C. Bendell Tamara Sauri Antonio Cubillo Gracián Rafael Alvarez Carlos López-López Pilar García-Alfonso Maen Hussein Maria-Luisa Limon Miron Andrés Cervantes Clara Montagut Cristina Santos Vivas Alberto Bessudo Patricia Plezia Veerle Moons Johannes Andel Jaafar Bennouna Andre van der Westhuizen Leslie Samuel Simona Rossomanno Christophe Boetsch Angelika Lahr Izolda Franjkovic Florian Heil Katharina Lechner Oliver Krieter Herbert Hurwitz for the McCAVE Study Group 《The oncologist》2020,25(3):e451-e459
999.
Michael T Milano Veronica L S Chiang Scott G Soltys Tony J C Wang Simon S Lo Alexandria Brackett Seema Nagpal Samuel Chao Amit K Garg Siavash Jabbari Lia M Halasz Melanie Hayden Gephart Jonathan P S Knisely Arjun Sahgal Eric L Chang 《Neuro-oncology》2020,22(12):1728
BackgroundThe American Radium Society (ARS) Appropriate Use Criteria brain malignancies panel systematically reviewed (PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses]) published literature on neurocognitive outcomes after stereotactic radiosurgery (SRS) for patients with multiple brain metastases (BM) to generate consensus guidelines.MethodsThe panel developed 4 key questions (KQs) to guide systematic review. From 11 614 original articles, 12 were selected. The panel developed model cases addressing KQs and potentially controversial scenarios not addressed in the systematic review (which might inform future ARS projects). Based upon quality of evidence, the panel confidentially voted on treatment options using a 9-point scale of appropriateness.ResultsThe panel agreed that SRS alone is usually appropriate for those with good performance status and 2–10 asymptomatic BM, and usually not appropriate for >20 BM. For 11–15 and 16–20 BM there was (between 2 case variants) agreement that SRS alone may be appropriate or disagreement on the appropriateness of SRS alone. There was no scenario (among 6 case variants) in which conventional whole-brain radiotherapy (WBRT) was considered usually appropriate by most panelists. There were several areas of disagreement, including: hippocampal sparing WBRT for 2–4 asymptomatic BM; WBRT for resected BM amenable to SRS; fractionated versus single-fraction SRS for resected BM, larger targets, and/or brainstem metastases; optimal treatment (WBRT, hippocampal sparing WBRT, SRS alone to all or select lesions) for patients with progressive extracranial disease, poor performance status, and no systemic options.ConclusionsFor patients with 2–10 BM, SRS alone is an appropriate treatment option for well-selected patients with good performance status. Future study is needed for those scenarios in which there was disagreement among panelists. 相似文献
1000.
Kathryn S Willebrand Lauren Pischel Amyn A Malik Samuel M Jenness Saad B Omer 《Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin》2022,27(1)
BackgroundCruise ships provide an ideal setting for transmission of SARS-CoV-2, given the socially dense exposure environment.AimTo provide a comprehensive review of COVID-19 outbreaks on cruise ships.MethodsPubMed was searched for COVID-19 cases associated with cruise ships between January and October 2020. A list of cruise ships with COVID-19 was cross-referenced with the United States Centers for Disease Control and Prevention’s list of cruise ships associated with a COVID-19 case within 14 days of disembarkation. News articles were also searched for epidemiological information. Narratives of COVID-19 outbreaks on ships with over 100 cases are presented.ResultsSeventy-nine ships and 104 unique voyages were associated with COVID-19 cases before 1 October 2020. Nineteen ships had more than one voyage with a case of COVID-19. The median number of cases per ship was three (interquartile range (IQR): 1–17.8), with two notable outliers: the Diamond Princess and the Ruby Princess, which had 712 and 907 cases, respectively. The median attack rate for COVID-19 was 0.2% (IQR: 0.03–1.5), although this distribution was right-skewed with a mean attack rate of 3.7%; 25.9% (27/104) of voyages had at least one COVID-19-associated death. Outbreaks involving only crew occurred later than outbreaks involving guests and crew.ConclusionsIn the absence of mitigation measures, COVID-19 can spread easily on cruise ships in a susceptible population because of the confined space and high-density contact networks. This environment can create superspreader events and facilitate international spread. 相似文献